BR112014032987A2 - método de tratamento ou profilaxia de um distúrbio neurológico - Google Patents
método de tratamento ou profilaxia de um distúrbio neurológicoInfo
- Publication number
- BR112014032987A2 BR112014032987A2 BR112014032987A BR112014032987A BR112014032987A2 BR 112014032987 A2 BR112014032987 A2 BR 112014032987A2 BR 112014032987 A BR112014032987 A BR 112014032987A BR 112014032987 A BR112014032987 A BR 112014032987A BR 112014032987 A2 BR112014032987 A2 BR 112014032987A2
- Authority
- BR
- Brazil
- Prior art keywords
- prophylaxis
- treatment
- neurological disorder
- œmethod
- ago
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261668134P | 2012-07-05 | 2012-07-05 | |
PCT/EP2013/064063 WO2014006105A1 (en) | 2012-07-05 | 2013-07-03 | Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014032987A2 true BR112014032987A2 (pt) | 2017-06-27 |
Family
ID=48741180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014032987A BR112014032987A2 (pt) | 2012-07-05 | 2013-07-03 | método de tratamento ou profilaxia de um distúrbio neurológico |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2870177A1 (es) |
JP (1) | JP2015521992A (es) |
KR (1) | KR20150036398A (es) |
CN (1) | CN104395343A (es) |
AU (1) | AU2013285493A1 (es) |
BR (1) | BR112014032987A2 (es) |
CA (1) | CA2876284A1 (es) |
IN (1) | IN2014KN02952A (es) |
RU (1) | RU2014150265A (es) |
WO (1) | WO2014006105A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102279751B1 (ko) * | 2019-06-28 | 2021-07-21 | 경북대학교 산학협력단 | 근원성 인자 또는 nogo-a 측정 제제를 포함하는 근육병 진단용 조성물과 이를 이용한 근육병 진단 방법 |
KR102409771B1 (ko) * | 2020-06-17 | 2022-06-16 | 경북대학교 산학협력단 | Nogo-A 및 필라민-C의 상호 결합을 이용한 근육질환의 치료제 스크리닝 방법 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
DE10336350B4 (de) | 2003-08-08 | 2007-10-31 | Westfalia Separator Ag | Vollmantel-Schneckenzentrifuge, mit Schälscheibe |
GB0321997D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
BRPI0417959A (pt) | 2003-12-22 | 2007-03-27 | Glaxo Group Ltd | anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável |
GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
ES2425768T3 (es) | 2007-11-02 | 2013-10-17 | Novartis Ag | Moléculas de unión a nogo-a mejoradas y uso farmacéutico de las mismas |
WO2010004031A2 (en) | 2008-07-11 | 2010-01-14 | Glaxo Group Limited | Novel treatment |
-
2013
- 2013-07-03 CA CA2876284A patent/CA2876284A1/en not_active Abandoned
- 2013-07-03 EP EP13732986.8A patent/EP2870177A1/en not_active Withdrawn
- 2013-07-03 KR KR20157003097A patent/KR20150036398A/ko not_active Application Discontinuation
- 2013-07-03 JP JP2015519214A patent/JP2015521992A/ja not_active Withdrawn
- 2013-07-03 BR BR112014032987A patent/BR112014032987A2/pt not_active IP Right Cessation
- 2013-07-03 RU RU2014150265A patent/RU2014150265A/ru not_active Application Discontinuation
- 2013-07-03 WO PCT/EP2013/064063 patent/WO2014006105A1/en active Application Filing
- 2013-07-03 IN IN2952KON2014 patent/IN2014KN02952A/en unknown
- 2013-07-03 CN CN201380035806.8A patent/CN104395343A/zh active Pending
- 2013-07-03 AU AU2013285493A patent/AU2013285493A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2870177A1 (en) | 2015-05-13 |
IN2014KN02952A (es) | 2015-05-08 |
CN104395343A (zh) | 2015-03-04 |
JP2015521992A (ja) | 2015-08-03 |
AU2013285493A1 (en) | 2015-01-22 |
KR20150036398A (ko) | 2015-04-07 |
RU2014150265A (ru) | 2016-08-27 |
WO2014006105A1 (en) | 2014-01-09 |
CA2876284A1 (en) | 2014-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500987A1 (en) | Heating element module for an aerosol-generating device | |
SG10201903962PA (en) | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme | |
MX2016017355A (es) | Lipido que comprende acido docosapentaenoico. | |
BR112015024674A2 (pt) | método para aumentar a capacidade de sobrevivência de um ou mais microrganismos benéficos e para revestir uma semente, e, composição | |
MX2015012401A (es) | Composiciones y metodos de alterar niveles de colesterol. | |
PH12016501160A1 (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
MX2015008766A (es) | Compuestos cbd fluorados, composiciones y usos de los mismos. | |
BR112016012840A2 (pt) | Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre | |
BR112013000768A2 (pt) | asparaginase de basidiomicetos | |
MX2014010959A (es) | Preparaciones de ester de acido fosforico con higroscopia reducida. | |
MX2015010077A (es) | Terapia de combinacion para el tratamiento de neumonia nosocomial. | |
EA201590744A1 (ru) | Лечение рака tor киназными ингибиторами | |
PH12016500903A1 (en) | Novel methods for treating neurodegenerative diseases | |
UY32075A (es) | Estabilización de preparaciones acuosas de minerales mediante reuterina | |
BR112015031541A2 (pt) | métodos para o impedimento da agregação de componentes virais | |
EA201491581A1 (ru) | Везикулярные композиции | |
BR112014032987A2 (pt) | método de tratamento ou profilaxia de um distúrbio neurológico | |
CL2015002069A1 (es) | Métodos para el uso de compuestos de fenoxipropilamina para tratar la depresión. | |
MX338405B (es) | Formulaciones de 2-iminobiotina y sus usos. | |
MX2013000539A (es) | Nuevas formulaciones de analogos 14-epi de la vitamina d. | |
EA201691036A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
MX370176B (es) | Método para el tratamiento y/o prevención contra encefalopatia traumática cronica grado i. | |
BR112015020874A2 (pt) | copropriedade de grupo de recursos acessíveis pela internet | |
MX2015006616A (es) | Doble direccion. | |
UY35165A (es) | Método profiláctico o terapéutico para el síndrome de sjogren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 4A ANUIDADE. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |